Converging lines of evidence indicate that defects in the mitochondrial electron transport chain (ETC) are associated with bipolar disorder (BD), and that mood-stabilizing drugs produce neuroprotective effects. Our objective is to review the most recent findings regarding this research.
Method:
We searched MEDLINE and have reviewed here the most recently published articles.
Results:
There are deletions, mutation, and decreased expression of mitochondrial ETC complexes in BD. Because ETC is a major source of reactive oxygen species, these factors, along with decreased expression of antioxidant enzymes in BD, suggest the presence of oxidative damage in this disorder. Numerous recent studies have shown that mood-stabilizing drugs produce neuroprotective effects against oxidative damage and increase expression and activities of endogenous antioxidant enzymes in the rat brain.
Conclusion:
These findings indicate that the process of oxidative damage could be a significant therapeutic target for the treatment of BD with mood-stabilizing drugs.
TondoLIsacssonGBaldessariniR.Suicidal behaviour in bipolar disorder: Risk and prevention. CNS Drugs. 2003;17:491–511.
2.
AngstFStassenHHClaytonPJMortality of patients with mood disorders: Follow-up over 34–38 years. J Affect Disord. 2002;68:167–181.
3.
StimmelGL. Economic grand rounds: The economic burden of bipolar disorder. Psychiatr Serv. 2004;55:117–118.
4.
WoodsSW. The economic burden of bipolar disease. J Clin Psychiatry. 2000;61(Supp 13):38–41.
5.
SoaresJCMannJJ. The anatomy of mood disorders eview of structural neuroimaging studies. Biol Psychiatry. 1997;41:86–106.
6.
DrevetsWCOngurDPriceJL. Neuroimaging abnormalities in the subgenual prefrontal cortex: Implications for the pathophysiology of familial mood disorders. Mol Psychiatry. 1998;3:220–226, 190–191.
7.
VawterMPFreedWJKleinmanJE. Neuropathology of bipolar disorder. Biol Psychiatry. 2000;48:486–504.
8.
DrevetsWCPriceJLSimpsonJRSubgenal prefrontal cortex abnormalities in mood disorders. Nature. 1997;386:824–827.
9.
RajkowskaG.Morphometric methods for studying the prefrontal cortex in suicide victims and psychiatric patients. Ann N Y Acad Sci. 1997;836:253–268.
10.
SoaresJCMannJJ. The functional neuroanatomy of mood disorders. J Psychiatr Res. 1997;31:393–432.
11.
RajkowskaGHalarisASelemonLD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry. 2001;49:741–752.
12.
BenesFMKwokEWVincentSLA reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol Psychiatry. 1998;44:88–97.
13.
BenesFMVincentSLTodtenkopfM.The density of pyramidal and nonpyramidal neurons in anterior cingulate cortex of schizophrenic and bipolar subjects. Biol Psychiatry. 2001;50:395–406.
14.
OngurDDrevetsWCPriceJL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA1998;95:13290–13295.
15.
BezchlibnykYBSunXWangJFNeuron somal size is decreased in the lateral amygdalar subnucleus from subjects with bipolar disorder. J Psychiatry Neurosci. 2007;32:203–210.
16.
Adam-ViziV.Production of reactive oxygen species in brain mitochondria: Contribution by electron transport chain and non-electron transport chain sources. Antioxid Redox Signal. 2005;7:1140–1149.
17.
GenovaMLBianchiCLenazG.Structural organization of the mitochondrial respiratory chain. Ital J Biochem. 2003;52:58–61.
18.
SchaggerH.Respiratory chain supercomplexes. IUBMB Life. 2001;52:119–128.
19.
MoroMAAlmeidaABolanosJPMitochondrial respiratory chain and free radical generation in stroke. Free Radic Biol Med. 200515;39:1291–1304.
20.
StadtmanER. Protein oxidation and aging. Science. 1992;257:1220–1224.
21.
ImlayJALinnS.DNA damage and oxygen radical toxicity. Science. 1988;240;1302–1309.
22.
SkaperSDFloreaniMCecconMExcitotoxicity, oxidative stress, and the neuroprotective potential of melatonin. Ann NY Acad Sci. 1999;890:107–118.
23.
YoudimMBLavieLRiedererP.Oxygen free radicals and neurodegeneration in Parkinson's disease: A role for nitric oxide. Ann NY Acad Sci. 1994;738:64–68.
24.
BealMF. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann Neurol. 1998;44:110–114.
25.
ShimohamaS.Apoptosis in Alzheimer's disease–an update. Apoptosis. 2000;5:9–16.
26.
MulthaupGRuppertTSchlicksuppAReactive oxygen species and Alzheimer disease. Biochem Pharmacol. 1997;54:533–539.
27.
DattaKSinhaSChattopadhyayP.Reactive oxygen species in health and disease. Natl Med J India. 2000;13:304–310.
28.
YaoJKReddyRDvan KammenDP. Oxidative damage and schizophrenia: An overview of the evidence and its therapeutic implications. CNS Drugs. 2001;15:287–310.
29.
GrimaGBenzBParpuraVDopamine-induced oxidative stress in neurons with glutathione deficit: Implication for schizophrenia. Schizophr Res. 2003;62:213–224.
30.
ChinopoulosCAdam-ViziV.Calcium, mitochondria and oxidative stress in neuronal pathology. Novel aspects of an enduring theme. FEBS J. 2006;273:433–450.
31.
GunterTEYuleDIGunterKKCalcium and mitochondria. FEBS Lett. 2004;567:96–102.
32.
GogvadzeVOrreniusSZhivotovskyB.Multiple pathways of cytochrome c release from mitochondria in apoptosis. Biochim Biophys Acta. 2006;1757:639–647.
33.
KatoTTakahashiSShioiriTBrain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 1992;26:223–230.
34.
KatoTTakahashiSShioiriTReduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J Affect Disord. 1994;31:125–133.
35.
KatoTShioiriTMurashitaJLateralized abnormality of high energy phosphate metabolism in the frontal lobes of patients with bipolar disorder detected by phase-encoded 31P-MRS. Psychol Med. 1995;25:557–566.
36.
HamakawaHKatoTShioiriTQuantitative proton magnetic resonance spectroscopy of the bilateral frontal lobes in patients with bipolar disorder. Psychol Med. 1999;29:639–644.
37.
DeickenRFFeinGWeinerMW. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. Am J Psychiatry. 1995;152:915–918.
38.
VolzHPRzannyRRiehemannS31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. Eur Arch Psychiatry Clin Neurosci. 1998;248:289–295.
39.
MooreCMChristensenJDLaferBLower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: A phosphorous-31 magnetic resonance spectroscopy study. Am J Psychiatry. 1997;154:116–118.
40.
KatoTTakahashiSShioiriTAlterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J Affect Disord. 1993;27:53–59.
41.
HamakawaHMurashitaJYamadaNReduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin Neurosci. 2004;58:82–88.
42.
KatoTMurashitaJKamiyaADecreased brain intracellular pH measured by 31P-MRS in bipolar disorder: A confirmation in drug-free patients and correlation with white matter hyperintensity. Eur Arch Psychiatry Clin Neurosci. 1998;248:301–306.
43.
SunXWangJFTsengMDown regulation in components of mitochondrial electron transport chain in post-mortem frontal cortex from subjects with bipolar disorder. J Psychiatry Neurosci. 2006;31:189–196.
44.
DagerSRFriedmanSDParowABrain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry. 2004;61:450–458.
45.
PurdonADRapoportSI. Energy requirements for two aspects of phospholipid metabolism in mammalian brain. Biochem J. 1998;335:313–318.
MooreGJGallowayMP. Magnetic resonance spectroscopy: Neurochemistry and treatment effects in affective disorders. Psychopharmacol Bull. 2002;36:5–23.
48.
HamakawaHKatoTMurashitaJQuantitative proton magnetic resonance spectroscopy of the basal ganglia in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci. 1998;248:53–58.
49.
DavanzoPYueKThomasMAProton magnetic resonance spectroscopy of bipolar disorder versus intermittent explosive disorder in children and adolescents. Am J Psychiatry. 2003;160:1442–1452.
50.
SharmaRVenkatasubramanianPNBaranyMProton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res. 1992;8:43–49.
51.
YildizASachsGSDorerDJ31P nuclear magnetic resonance spectroscopy findings in bipolar illness: A meta-analysis. Psychiatry Res. 2001;106:181–191.
52.
HahnCGGomezGRestrepoDAberrant intracellular calcium signaling in olfactory neurons from patients with bipolar disorder. Am J Psychiatry. 2005;162:616–618.
53.
EmamghoreishiMSchlichterLLiPPHigh intracellular calcium concentrations in transformed lymphoblasts from subjects with bipolar I disorder. Am J Psychiatry. 1997;154:976–982.
54.
DubovskySLThomasMHijaziAIntracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur Arch Psychiatry Clin Neurosci. 1994;243:229–234.
55.
YoonISLiPPSiuKPAltered IMPA2 gene expression and calcium homeostasis in bipolar disorder. Mol Psychiatry. 2001;6:678–683.
56.
KatoTStineOCMcMahonFJIncreased levels of a mitochondrial DNA deletion in the brain of patients with bipolar disorder. Biol Psychiatry. 1997;42:871–875.
57.
KatoTKunugiHNankoSMitochondrial DNA polymorphisms in bipolar disorder. J Affect Disord. 2001;62:151–164.
58.
KatoTKunugiHNankoSAssociation of bipolar disorder with the 5178 polymorphism in mitochondrial DNA. Am J Med Genet. 2000;96:182–186.
59.
TanakaMGongJ-SZhangJMitochondrial genotype associated with longevity. Lancet. 1998;351:185–186.
60.
CanterJAKallianpurARParlFFMitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 2005;65:8028–8033.
61.
MunakataKTanakaMMoriKMitochondrial DNA 3644T C mutation associated with bipolar disorder. Genomics. 2004;84:1041–1050.
62.
WashizukaSIwamotoKKazunoAAAssociation of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the National Institute of Mental Health pedigrees. Biol Psychiatry. 2004;56:483–489.
63.
WashizukaSKakiuchiCMoriKAssociation of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet. 2003;120:72–78.
64.
de CooRBuddigerPSmeetsHMolecular cloning and characterization of the active human mitochondrial NADH: Ubiquinone oxidoreductase 24-kDa gene (NDUFV2) and its pseudogene. Genomics. 1995;26:461–466.
65.
Detera-WadleighSDBadnerJABerrettiniWHA high-density genome scan detects evidence for a bipolar-disorder susceptibility locus on 13q32 and other potential loci on 1q32 and 18p11.2. Proc Natl Acad Sci USA. 1999;96:5604–5609.
66.
EsterlingLEMatiseT CoxSandersARAn integrated physical map of 18p11.2: A susceptibility region for bipolar disorder. Mol Psychiatry. 1997;2:501–504.
67.
HalliwellB.Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:1609–1623.
68.
KonradiCEatonMMacDonaldMLMolecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry. 2004;61:300–308.
69.
IwamotoKBundoMKatoT.Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum Mol Genet. 2005;14:241–253.
70.
ChengRJuoSHLothJEGenome-wide linkage scan in a large bipolar disorder sample from the National Institute of Mental Health genetics initiative suggests putative loci for bipolar disorder, psychosis, suicide, and panic disorder. Mol Psychiatry. 2006;11:252–260.
71.
BezchlibnykYBWangJFMcQueenGMGene expression differences in bipolar disorder revealed by cDNA array analysis of post-mortem frontal cortex. J Neurochem. 2001;79:826–834.
72.
BenesFMMatzilevichDBurkeREThe expression of proapoptosis genes is increased in bipolar disorder, but not in schizophrenia. Mol Psychiatry. 2006;11:241–251.
73.
KulogluMUstundagBAtmacaMLipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002;20:171–175.
74.
RanjekarPKHingeAHegdeMVDecreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res. 2003;121:109–122.
75.
OzcanMEGulecMOzerolEAntioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 2004;19:89–95.
76.
FreyBNAndreazzaACKunzMIncreased oxidative stress and DNA damage in bipolar disorder: A twin-case report. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:283–285.
77.
WangJFAzzamJEYoungLT. Valproate inhibits oxidative damage to lipid and protein in primary cultured rat cerebrocortical cells. Neuroscience. 2003;116:485–489.
78.
ShaoLYoungLTWangJF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry. 2005;58:879–884.
79.
LaiJSZhaoCWarshJJCytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol. 2006;539:18–26.
80.
KingTDJopeRS. Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport. 2005;16:597–601.
81.
CuiJShaoLYoungLTRole of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience. 2007;144:1447–1453.
82.
SchaferMGoodenoughSMoosmannBInhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res. 2004;1005:84–89.
83.
LiNRaghebKLawlerGMitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem. 2003;278:8516–8525.
84.
WeiZBaiORichardsonJSOlanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide. J Neurosci Res. 2003;73:364–368.
85.
WangHXuHDyckLEOlanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25–35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res. 2005;81:572–580.
86.
FreyBNValvassoriSSReusGZEffects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci. 2006;31:326–332.
87.
WangJFShaoLSunXGlutathione S-transferase is a novel target for mood stabilizing drugs in primary cultured neurons. J Neurochem. 2004;88(6):1477–1484.
88.
WangJFShaoLCuiJThe effect of mood stabilizing drug lithium on expression and activity of glutathione s-transferase isoenzymes in primary cultured rat cerebral cortical cells. Free Radical Research. 2006;40:S159.
89.
SharmaRYangYSharmaAAntioxidant role of glutathione S-transferases: Protection against oxidant toxicity and regulation of stress-mediated apoptosis. Antioxid Redox Signal. 2004;6:289–300.
90.
ShuklaGS. Mechanism of lithium action: In vivo and in vitro effects of alkali metals on brain superoxide dismutase. Pharmacol Biochem Behav. 1987;26:235–240.
91.
de VasconcellosAPNietoFBCremaLMChronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem Res. 2006;31:1141–1151.
92.
LiXMChlan-FourneyJJuorioAVDifferential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res. 1999;56:72–75.
93.
ReiterRJAcuna-CastroviejoDTanDXFree radical-mediated molecular damage. Mechanisms for the protective actions of melatonin in the central nervous system. Ann N Y Acad Sci. 2001;939:200–215.
94.
DjordjevicVB. Free radicals in cell biology. Int Rev Cytol. 2004;237:57–89.
95.
ChenBWangJFYoungLT. Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol Psychiatry. 2000;48:658–664.
96.
WangJFBownCYoungLT. Differential display PCR reveals novel targets for the mood-stabilizing drug valproate including the molecular chaperone GRP78. Mol Pharmacol. 1999;55:521–527.
97.
ShaoLSunXXuLMood stabilizing drug lithium increases expression of endoplasmic reticulum stress proteins in primary cultured rat cerebral cortical cells. Life Sci. 2006;78:1317–1323.
98.
HiroiTWeiHHoughCProtracted lithium treatment protects against the ER stress elicited by thapsigargin in rat PC12 cells: Roles of intracellular calcium, GRP78 and Bcl-2. Pharmacogenomics J. 2005;5:102–111.
99.
LeeAS. The glucose-regulated proteins: Stress induction and clinical applications. Trends Biochem Sci. 2001;26:504–510.
100.
YuZLuoHFuWThe endoplasmic reticulum stress-responsive protein GRP78 protects neurons against excitotoxicity and apoptosis: Suppression of oxidative stress and stabilization of calcium homeostasis. Exp Neurol. 1999;155:302–314.
101.
NigamSKGoldbergALHoSA set of endoplasmic reticulum proteins possessing properties of molecular chaperones includes CA2+ binding proteins and member of the thioredoxin superfamily. J Biol Chem. 1994;269:1744–1749.
102.
ChenRWChuangDM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem. 1999;274:6039–6042.
103.
ChenGZengWZYuanPXThe mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999;72:879–882.
104.
DongGXSinghDKDendlePRegional expression of Bcl-2 mRNA and mitochondrial cytochrome c release after experimental brain injury in the rat. Brain Res. 2001;903:45–52.
105.
KowaltowskiAJVercesiAEFiskumG.Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides. Cell Death Differ. 2000;7:903–910.
106.
ChenRWQinZHRenMRegulation of c-Jun N-terminal kinase, p38 kinase and AP-1 DNA binding in cultured brain neurons: Roles in glutamate excitotoxicity and lithium neuroprotection. J Neurochem. 2003;84:566–575.
107.
GhribiOPrammonjagoPHermanMMAbeta(1–42)-induced JNK and ERK activation in rabbit hippocampus is differentially regulated by lithium but is not involved in the phosphorylation of tau. Brain Res Mol Brain Res. 2003;119:201–206.
108.
Pandi-PerumalSRSrinivasanVMaestroniGJMelatonin: Nature most versatile biological signal?FEBS J. 2006;273:2813–2838.
109.
GaoKCalabreseJR. Newer treatment studies for bipolar depression. Bipolar Disord. 2005;7:13–23.
